Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B01AE06
|
| gptkbp:CASNumber |
128270-60-0
|
| gptkbp:contraindication |
active bleeding
hypersensitivity to bivalirudin |
| gptkbp:developedBy |
gptkb:The_Medicines_Company
|
| gptkbp:eliminationHalfLife |
25 minutes
|
| gptkbp:genericName |
gptkb:bivalirudin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Angiomax
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
direct thrombin inhibitor
|
| gptkbp:pregnancyCategory |
B (Australia)
|
| gptkbp:proteinBinding |
25%
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea bleeding headache |
| gptkbp:usedFor |
anticoagulation
percutaneous coronary intervention |
| gptkbp:bfsParent |
gptkb:The_Medicines_Company
|
| gptkbp:bfsLayer |
6
|